Formulation and characterization of transdermal patch of Candesartan Celexitil was written by Shabnam, Hira;Singh, Dua Jagdeep;Prasad, D. N.;Anchal, Puri;Sahil, Kaushal. And the article was included in Journal of Drug Delivery and Therapeutics in 2019.Computed Properties of C33H34N6O6 This article mentions the following:
The aim of the present study is to formulate and characterized the transdermal patch of Candesartan celexitil. The objective is study was to increase the bioavailability of drug. In the present study, transdermal patch of Candesartan celexitil were prepared by solvent casting technique employing HPMC cps 50 polymer and glycerin as plasticizer using mercury as substrate. Total thirteen formulation (F1-F13) were prepared having drug and polymer ratio (1:2, 1:4, 1:6, 1:8, and 1:10). From the selected batch F2 containing drug polymer ratio (1:4), four formulations each were prepared and evaluated containg drug urea (1-4%) and oleic acid (1-4%) as permeation enhancer. The prepared transdermal patches were evaluated on the basis of different parameters like weigh, thickness, folding endurance, percent moisture absorption, percent moisture loss, drug content uniformity, in vitro skin permeation study. The fabricated final transdermal patches were further subjected to in vitro permeation study. In order to confirm the exact mechanism of drug release from all the patches, the data were computed and graphed according to Korsmeyer equation. Diffusion exponent of release process controlled by Super case II transport Non- Fickian diffusion, n values of Korsmeyer- Peppas model shows a combination of diffusion and dissolution mechanism indicating the drug release from the formulation was controlled by more than one process. It was concluded that the prepared formulation F13 (4% w/v of oleic acid) showed highest cumulative percent drug release and increase the bioavailability of the drug. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Computed Properties of C33H34N6O6).
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Computed Properties of C33H34N6O6
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem